Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Public ClinicalTrials.gov record NCT05694884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Study identification
- NCT ID
- NCT05694884
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2022
- Primary completion
- Dec 30, 2024
- Completion
- Feb 27, 2025
- Last update posted
- Jan 17, 2024
2022 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ASLAN Investigative Site | Birmingham | Alabama | 35244 | Recruiting |
| ASLAN Investigative Site | Encino | California | 91436 | Recruiting |
| ASLAN Investigative Site | Fountain Valley | California | 92708 | Recruiting |
| ASLAN Investigative Site | Long Beach | California | 90806 | Recruiting |
| ASLAN Investigative Site | Los Angeles | California | 90025 | Recruiting |
| ASLAN Investigative Site | Sherman Oaks | California | 91403 | Recruiting |
| ASLAN Investigative Site | Boca Raton | Florida | 33486 | Recruiting |
| ASLAN Investigative Site | Hollywood | Florida | 33021 | Recruiting |
| ASLAN Investigative Site | Hollywood | Florida | 33436 | Recruiting |
| ASLAN Investigative Site | Miami Lakes | Florida | 33014 | Recruiting |
| ASLAN Investigative Site | North Miami Beach | Florida | 33162 | Recruiting |
| ASLAN Investigative Site | Orange City | Florida | 32720 | Recruiting |
| ASLAN Investigative Site | Saint Augustine | Florida | 32080 | Recruiting |
| ASLAN Investigative Site | St. Petersburg | Florida | 33705 | Recruiting |
| ASLAN Investigative Site | New Albany | Indiana | 47150 | Recruiting |
| ASLAN Investigative Site | Louisville | Kentucky | 40217 | Recruiting |
| ASLAN Investigative Site | Quincy | Massachusetts | 02169 | Recruiting |
| ASLAN Investigative Site | Auburn Hills | Michigan | 48326 | Recruiting |
| ASLAN Investigative Site | Las Vegas | Nevada | 89148 | Recruiting |
| ASLAN Investigative Site | East Amherst | New York | 14051 | Recruiting |
| ASLAN Investigative Site | Charlotte | North Carolina | 28277 | Recruiting |
| ASLAN Investigative Site | Oklahoma City | Oklahoma | 73118 | Recruiting |
| ASLAN Investigative Site | Johnston | Rhode Island | 02919 | Recruiting |
| ASLAN Investigative Site | Charleston | South Carolina | 29407 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05694884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 17, 2024 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05694884 live on ClinicalTrials.gov.